checkAd

    DGAP-News  751  0 Kommentare MOLOGEN AG: New strategic orientation, successful capital measures and notable study progress in 2016





    DGAP-News: MOLOGEN AG / Key word(s): Final Results


    MOLOGEN AG: New strategic orientation, successful capital measures and notable study progress in 2016


    22.03.2017 / 07:05



    The issuer is solely responsible for the content of this announcement.



    MOLOGEN AG: New strategic orientation, successful capital measures and notable study progress in 2016



    - Ongoing implementation of the new "Next Level" corporate strategy



    - Funding secured until the start of 2018 through capital measures



    - Lead product lefitolimod: significant milestones reached



    - Changes to Executive Board



    - Confident forecast for 2017





    Berlin, 22 March 2017 - MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) had an eventful and positive fiscal year 2016. Almost all key milestones were reached in the last financial year. The main focus was on developing and implementing the new "Next Level" corporate strategy, with its clear concentration on the further development of the lead product candidate, the immunotherapy lefitolimod. All four current studies with lefitolimod have reported good progress. In particular, initial positive results were presented for the TEACH study in the indication human immunodeficiency virus (HIV). In addition, the first combination study of lefitolimod with another immunotherapeutic agent started in the reporting period. As expected, the study advancements resulted in a slight increase in expenditure in the area of research and development.



    MOLOGEN secured the future funding - for both the company's new alignment and the continuation of studies with lefitolimod and the follow-up molecules EnanDIM(R) - through two successfully completed capital measures, with the capital increase and the convertible bond generating gross proceeds of EUR16.1 million in total.



    Over the past financial year, there were two changes on the Executive Board of MOLOGEN AG: since 1 April 2016, Walter Miller has been the new Chief Financial Officer (CFO) of MOLOGEN AG. On 31 March 2016, the Chief Medical Officer (CMO) Dr. Alfredo Zurlo left the company. He is being succeeded by Dr. Matthias Baumann, who will start in his new position on 1 May 2017.

    Seite 1 von 6


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News MOLOGEN AG: New strategic orientation, successful capital measures and notable study progress in 2016 DGAP-News: MOLOGEN AG / Key word(s): Final Results MOLOGEN AG: New strategic orientation, successful capital measures and notable study progress in 2016 22.03.2017 / 07:05 The issuer is solely responsible for the content of this announcement. …